Trial Profile
Efficacy and safety of Nivolumab in patients with non small cell lungcancer with preexisting interstitial lung disease: a retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Nov 2017 New trial record
- 18 Oct 2017 Results assessing efficacy and safety presented at the 18th World Conference on Lung Cancer.